Thierry Calvez
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Compliance with Early Long-Term Prophylaxis Guidelines for Severe Hemophilia A.
Journal: The Journal of pediatrics
Published: October 10, 2020
Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: August 27, 2018
FranceCoag: a 22-year prospective follow-up of the national French cohort of patients with inherited bleeding disorders.
Journal: European journal of epidemiology
Published: June 29, 2018
Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.
Journal: Haematologica
Published: June 16, 2017
Response: Confounding by indication is unlikely to explain the higher inhibitor incidence in boys treated with a recombinant FVIII product.
Journal: Blood
Published: June 13, 2015
EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France.
Journal: Transfusion
Published: October 07, 2014
In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: September 10, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026